Short Interest in Prenetics Global Limited (NASDAQ:PRE) Drops By 20.8%

Prenetics Global Limited (NASDAQ:PRE) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 23,600 shares, a decline of 20.8% from the April 30th total of 29,800 shares. Based on an average trading volume of 15,900 shares, the short-interest ratio is presently 1.5 days. Approximately 0.3% of the shares of the stock are sold short.

Hedge Funds Weigh In On Prenetics Global

An institutional investor recently raised its position in Prenetics Global stock. Nomura Holdings Inc. raised its holdings in shares of Prenetics Global Limited (NASDAQ:PRE) by 3.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 333,528 shares of the company’s stock after buying an additional 10,576 shares during the period. Nomura Holdings Inc. owned about 2.73% of Prenetics Global worth $1,307,000 at the end of the most recent reporting period. 25.01% of the stock is currently owned by institutional investors and hedge funds.

Prenetics Global Trading Down 5.5%

Shares of PRE stock traded down $0.51 on Tuesday, reaching $8.69. The company’s stock had a trading volume of 8,900 shares, compared to its average volume of 19,009. Prenetics Global has a 1 year low of $3.09 and a 1 year high of $11.99. The stock’s fifty day simple moving average is $5.59 and its 200-day simple moving average is $5.31. The company has a market capitalization of $106.06 million, a price-to-earnings ratio of -2.18 and a beta of -0.26.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.